Medivir Licenses China Rights for Cold Sore Treatment to Daewoong
June 24, 2011 at 05:22 AM EDT
Medivir AB, a Swedish biopharma focused on infectious diseases, out-licensed exclusive China rights for its cold sore treatment, Xerclear® to Daewoong Pharma of South Korea. Daewoong will be responsible for conducting clinical trials and obtaining SFDA approval on the product. Medivir will receive royalties on sales of Xerclear, which was first approved in the US and Europe in 2009. More details.... Stock Symbol: (OMX: MVIR) Share this with colleagues:
